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Das inflammatorische Milieu bei Patienten mit einer chronischer Nierenerkrankung 
(CNI) ist ein Risikofaktor für vaskuläre Komorbiditäten. Bislang sind verschiedene 
Biomarker hierfür bei CNI Patienten identifiziert, einer davon ist das Serumamyloid 
A (SAA). SAA ist ein Akut-Phase-Protein, dass hauptsächlich im „high-
density“ Lipoprotein (HDL) akkumuliert und die endogen entzündungshemmende 
Funktion von HDL reduziert. SAA aktiviert verschiedene Rezeptorklassen in 
vaskulären und inflammatorischen Zellen, u.a. „toll-like“ Rezeptoren (TLR) 2 und 
4.  
Der erste Teil der Studie hat zum Ziel, die Signalwege von SAA in Makrophagen 
zu studieren, hier insbesondere für die pro-inflammatorischen Zytokine IL-1β, IL-6 
und MCP-1, sowie die Nitrit- und ROS-Produktion. Die SAA-induzierte Zytokin-, 
Nitrit-Produktion ist in Makrophagen TLR2 und TLR4 vermittelt. Die IL-1ß 
Produktion ist intrazellulär über eine Aktivierung des NLRP3-Inflammasoms 
reguliert, wohingegen die Antagonisierung des NLRP3 Inflammasoms keinen 
Effekt auf die SAA-induzierte wurde in den Downstream-Pathway-Nachweis 
einbezogen. Laut dieser Studie IL-6, MCP-1 und Nitrit-Produktion zeigte.  
Da die SAA Plasmakonzentration bei CNI-Patienten durch eine regelmäßige 
Dialysebehandlung nicht effizient gesenkt werden kann, sollten im zweiten Teil 
dieser Studie Methoden zur Entfernung von SAA aus dem Blutkreislauf untersucht 
werden. CytoSorbTM adsorber erwies sich als vielversprechendes Material zur 







The inflammatory environment in patients with chronic kidney disease (CKD) is a 
risk factor for vascular comorbidities. To date, several biomarkers have been 
identified in CKD patients; where one of it is serum amyloid A (SAA). SAA is an 
acute-phase protein that accumulates mainly in the high-density lipoprotein (HDL) 
and reduces the endogenous anti-inflammatory function of HDL. SAA activates 
various receptor classes in vascular and inflammatory cells, such as Toll-like 
receptors (TLRs) 2 and 4. 
The first part of the study aims to investigate the signaling pathways of SAA in 
macrophages, in particular for the proinflammatory cytokines IL-1β, IL-6 and MCP-
1, as well as nitrite and ROS production. The SAA-induced cytokines, nitrite 
production are mediated in macrophages via TLR2 and TLR4. IL-1β production is 
regulated intracellularly via activation of the NLRP3 inflammasome, whereas an 
antagonist of the NLRP3 inflammasome has no effect on SAA-induced IL-6, MCP-
1 and nitrite production. 
Because SAA plasma concentrations in CKD patients cannot be effectively 
reduced by regular dialysis treatment, the second part of this study explored 
methods for removing SAA from the bloodstream. The CytoSorbTM adsorber 
proved to be a promising material for removing SAA from plasma.  





Chronic kidney disease (CKD) is one of the fastest growing causes of death worldwide in the 
past decade1. In addition, an inflammatory environment, which contributes to the increased 
mortality has been described for CKD patients2,3. Studies in recent years have shown great 
interest in the mechanism behind this inflammatory state. A proinflammatory protein named 
serum amyloid A (SAA) was found contribute to this situation. In CKD patients, SAA 
increases to a moderate level (10-30-fold increase). With this increase, SAA replaces of 
Apolipoprotein A I (apoA-I) and subsequently modifies the component, impairs the anti-
inflammatory function of high-density lipoprotein (HDL)4,5. The HDL function impairment by 
SAA has been well demonstrated in a multicenter and long-term follow-up study6. This study 
recruited approximately 9,000 subjects including CKD patients. In patients with high SAA 
levels, the HDL level positively correlated with all- and cardiovascular-cause mortalities, 
while in normal-SAA-level patients, the HDL concentration negatively associated with these 
two mortalities. In addition to modifying the HDL component, SAA itself acts as a 
proinflammatory mediator and induces cytokine and chemokine expression in different cells. 
Given the critical role of SAA in the inflammatory response, the detailed mechanism of SAA 
pathogenicity needs to be explored and better understood.  
1.1 SAA physiology  
SAA is an acute phase reaction protein which increases over 1000-fold during acute phase 
responses7. There are four isotypes of human SAA, which are SAA1, SAA2, SAA3 and SAA4. 
SAA4 is considered as a constant SAA (C-SAA) due to its continuous and extensive 
expression8, while human SAA3 has only been found in mammary gland epithelial cells at 
the transcriptional level9. In acute phase responses, SAA1 and SAA2 contribute to the major 
increase in SAA in the circulation (increases from 1-2 µg/ml to 1 mg/ml). 
SAA is mainly synthesized in the liver but its expression is also found in other cells and 
organs, especially under inflammatory conditions10. The production of A-SAA is a synergistic 
with that of several cytokines. The A-SAA gene is required for full induction by IL-1 and IL-
611. IL-1 is the leading cytokine to induce SAA, followed by IL-6, TNF-α and glucocorticoids12-






After its release into the circulation, SAA associates with HDL as an apolipoprotein, 
predominantly with HDL3. In addition, SAA can also associate with low-density lipoprotein 
(LDL) and very-low-density lipoprotein (VLDL)17. In acute phase responses, the SAA/total 
HDL protein ratio can rise from 1/2 to 5018. With this upsurge, SAA displaces apoA-I from 
HDL and becomes the major apolipoprotein of HDL19. The binding site for SAA in HDL is still 
not clear. One study found that SAA binds to lipoproteins by a hydrophobic surface formed 
by two alpha-helical structures in the N-domain20. In plasma, A-SAA has a short half-life, only 
lasting 1-2 h and is mainly degraded by the liver and kidney21,22. Cells such as monocytes 
and mast cells can also decrease SAA levels in the circulation23,24. Under inflammatory 
conditions, SAA is degraded less efficiently24,25. A genetic polymorphism also contributes to 
the different degradation rates of SAA26.  
Figure 1 shows the physiological process of SAA introduced above. According to this diagram, 
SAA further induces cytokines mediating a positive feedback inflammatory reaction. The 





Figure 1 Physiological process of SAA 
apoA-I, Apolipoprotein A I;  HDL, high-density lipoprotein; IL, interleukin; SAA, serum amyloid A; TNF-α, tumor 





1.2 The biofunction of SAA 
The function of C-SAA is not well known, but both pro- and anti-inflammatory properties of 
A-SAA have been revealed. Therefore, the following discussion regarding SAA is only about 
A-SAA. The anti-inflammatory function of SAA includes enhancing the opsonization of gram-
negative bacteria27,28 and neutrophil migration29, inhibiting hepatitis C virus entry into 
hepatocytes30,31, inducing retinol binding protein32 and M2 macrophage differentiation33, and 
suppressing antibody production34. On the other hand, SAA plays a more critical role in the 
immune response as an inflammatory mediator. As shown in Figure 1, SAA-induced 
cytokines can further promote SAA generation. This mutual induction process leads to an 
enhanced and sustained inflammatory reaction. In addition, SAA can also maintain this 
reaction by impairing the anti-inflammatory function of HDL. After enrichment with SAA, HDL 
loses its ability to inhibit inflammatory mediators such as MCP-1, IL-1, IL-6 and reactive 
oxygen species (ROS)4,5. Furthermore, SAA induces angiogenesis by upregulating 
intercellular adhesion molecule 1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-
1)35,36, which are components of inflammation.  
1.3 Receptors for SAA mediating inflammatory reaction 
SAA binds to receptors from different families (Figure 2) including scavenger receptor class 
B type 1 (SR-BI), receptor for advanced glycation end products (RAGE), P2X purinoceptor 
7 (P2X7), N-formyl peptide receptor 2 (FPR2), cluster of differentiation 36 (CD36) and Toll-
like-receptor 2 and 4 (TLR2/TLR4). These receptors can mediate distinct functions in cells. 
For instance, SR-BI is an HDL receptor that mediates cellular selective cholesterol ester 
uptake from HDL37. CD36 also belongs to the class B scavenger receptor family and can 
import fatty acids inside cells38. RAGE is a transmembrane multiligand receptor belonging to 
the immunoglobulin superfamily and plays a remarkable role in the pathogenesis of 
nephropathy39. FPR2 is a G protein-coupled receptor that recognizes N-formyl peptide (e.g., 
from bacteria) and mediates the immune response in phagocytes40. P2X7 is an ATP-gated 
ion channel that allows ion transcellular movement when activated by agonists41. Finally, 
both TLR2 and TLR4 are from the TLR family and recognize molecules that are broadly 
shared by pathogens, which play critical roles in host immune defense. Interestingly, all these 









Table 1 Receptors and pathways for SAA-mediated inflammatory reactions 
 
Receptors Target cells Activated pathway 
Induced cytokines 
and other proteins 
References 
TLR2 
Human monocytes CK-1, NF-κB G-CSF  42 
Mouse macrophages 
THP-1 monocytes and 
PBMCs 
IRF-7, TRAF6 IL-33  43 
Coronary artery 
endothelial cells 
JNK, ERK, NF-κB 
(p65, p105) 
IL-6, IL-8, G-CSF, GM-
CSF, ICAM-1 and 
VCAM-1  
36 





ICAM-1, IL-8, MCP-1, 
RANTES and CXCL1  
35  
Dermal fibroblasts IRAK4, NF-κB IL-6  45 
HeLa cells 
ERK, p38 MAPK, 
and JNK 
IL-10   46 





IL-1β  48 
Mouse macrophages 
THP-1 macrophages 
NLRP3 IL-1β 49 
 
 
Figure 2 Receptors for SAA 
SR-BI, scavenger receptor class B type 1; RAGE, receptor for advanced glycation end products, P2X7, P2X 
purinoceptor 7; FPR2, N-formyl peptide receptor 2; CD36, cluster differentiation 36; TLR2/TLR4, Toll-like-





Table 1 (continued) 
TLR4 









MD-2, MyD88, p38 
MAPK, JNK, Akt 





IL-8  53 
NA IL-6  54 
Mouse airway 
epithelial cells 
NA IL-8  55  
Vascular smooth 
muscle cells 
NA MCP-1  4 
SR-BI 
Rheumatoid arthritis 
synovial membrane  




MMP-2, and MMP-9 
TNF-α  
57 
RAGE Fibroblast-like synovial 
cells  
NF-κB  IL-6 and IL-8  58 
P2X7 Mouse macrophages, 
THP-1 macrophages 
NLRP3 IL-1β  49 
CD36 Rat macrophages JNK and ERK1/2 IL-8  59 
NA, data not available; CD36, cluster of differentiation 36; CK-1, casein kinase 1; CXCL 1, chemokine ligand 
1; ERK, extracellular signal–regulated kinases; FPR2, formyl peptide receptor 2; G-CSF, granulocyte colony-
stimulating factor; GM-CSF, granulocyte-macrophage colony-stimulating factor; HMGB1, high mobility group 
box 1; ICAM-1, intercellular adhesion molecule 1; IL, interleukin; IRF-7, interferon regulatory factor 7; JNK, c-
Jun N-terminal kinases; MAPK, Mitogen-activated protein kinase; MCP-1, monocyte chemoattractant protein 
1; MMP, matrix metalloproteinase; MyD88, Myeloid differentiation primary response 88; NF-κB, nuclear factor 
kappa-light-chain-enhancer of activated B cells; PBMCs, peripheral blood mononuclear cells; P2X7, P2X 
purinoceptor 7; RAGE, receptor for advanced glycation end products; SR-BI, scavenger receptor B1; TLR, Toll 
like receptor; TNF-α, tumor necrosis factor alpha; TRAF6, TNF receptor associated factor 6; VCAM-1, vascular 
cell adhesion molecule-1. 
 
1.4 Proinflammatory cytokines induced by SAA and the signaling pathways involved 
SAA (Table 1) can induce different cytokines through distinct receptors in diverse cell types. 
Among those cytokines, IL-1β can be upregulated very quickly, e.g., lipopolysaccharide (LPS) 
can increase IL-1β mRNA within 15 min and peak at 4 h60. After release from the cells, IL-
1β binds to the IL-1β receptor and promotes the secretion of other cytokines such as TNF-α 





monocytes and macrophages, in which its synthesis is stimulated upon the recognition by 
pattern recognition receptors (PRRs) of pathogen-associated molecular patterns (PAMPs) 
or damage-associated molecular patterns (DAMPs)63. IL-1β secretion is a two-step process 
that includes priming and activation. For instance, LPS can only prime cells and induce pro-
IL-1β rather than mature IL-1β64. The pro-IL-1β must to be further cleaved by caspase-1, 
which is activated by the NOD-like receptor, pyrin domain containing 3 (NLRP3) 
inflammasome, to finally be released as mature IL-1β65. During this unique and complicated 
process, in addition to the stimulation of PRRs, other activators might be indispensable for 
the production of mature IL-1β, e.g., extracellular adenosine triphosphate (ATP) is a NLRP3 
inflammasome activator required for the LPS-stimulated IL-1β secretion66. The NLRP3 
inflammasome can also be activated by potassium (K+) efflux, calcium (Ca2+) influx, ROS 
and mitochondrial dysfunction65. On the other hand, NLRP3 inflammasome- or Caspase-1-
independent IL-1β release has also been demonstrated in knockout mice67. Several studies 
have investigated the pathway for SAA-induced IL-1β. According to those research studies, 
SAA-induced IL-1β is NLRP3 inflammasome-caspase-1-dependent49,68. Furthermore, unlike 
LPS, no extra activator is required for SAA processing of IL-1β maturation69, possibly owing 
to the multireceptor activation by SAA. TLR2 and TLR4 are the two SAA receptors that 
promote IL-1β secretion48. However, these two receptors are involved in the priming step, 
which upregulates pro-IL-1β and NLRP348. The mechanism by which SAA activates the 
NLRP3 inflammasome and releases IL-1β is still unclear. P2X7 is an ATP-gated ion channel, 
that can release mature IL-1β via K+ efflux66. Thus, the role of this receptor in SAA-induced 
IL-1β has been investigated. However, two studies reached contradictory conclusions65,68. 
Another possible activator for SAA-mediated IL-1β maturation are ROS. The inhibition of 
ROS blocked IL-1β secretion in SAA-stimulated macrophages68, whereas another study 
indicated an increase in SAA-induced IL-1β production by mitochondrial-targeted drugs 
regardless of the ROS level69. Considering the inconsistent results, more investigations are 
needed to clarify these questions. 
In addition, IL-6, one of the major inducers of hepatic acute phase protein, is a cytokine that 
can be induced by SAA in diverse cells. IL-6 was initially found in monocytes and 
macrophages after LPS stimualtion70. The IL-6 biofunctions include facilitating the 





vascular permeability and angiogenesis71. Different receptors are involved in SAA-induced 
IL-6 secretion in different cell types. For example, SAA upregulates IL-6 in coronary artery 
endothelial cells and skeletal muscle cells via TLR236,44, while in fibroblast synovial cells and 
mouse macrophages, SAA promotes IL-6 secretion through TLR451,52. SR-BI and RAGE 
also act as the SAA receptors to induce IL-6 in rheumatoid arthritis synovial membranes and 
fibroblast-like synovial cells56,58.  
Moreover, MCP-1 is one of the most important SAA-induced chemokines, and plays a pivotal 
role in monocyte recruitment during inflammatory reactions. Due to this feature, MCP-1 
participates in bone remodeling, central nervous system (CNS) inflammation development 
and atherosclerotic lesion formation72. In atherosclerosis, the accumulated SAA can induce 
local inflammation by upregulating MCP-1 in monocytes and macrophages73. TLR2, TLR4 
and FPR2 have been demonstrated as receptors for SAA that mediate MCP-1 secretion4,35,51. 
As discussed before, IL-1β is an early response cytokine, that subsequently induces the 
generation of IL-6 and the other cytokines. The significantly reduced IL-6 found in IL-1β-
deficient mice is indicative of the IL-1β-dependent IL-6 synthesis61. While a recent study 
demonstrated different regulations of IL-1β and IL-6 in murine macrophages, showing that 
in J774.1 and RAW 264.7 cells, LPS and ATP failed to process pro-caspase-1 and pro-IL-
1β to their mature forms, the release of IL-6 was not affected74. Similarly, a NF-κB-binding 
site in the MCP-1 gene was found to be a critical element in MCP-1 induction in response to 
IL-1β72. Accordingly, these SAA-induced cytokines might interact with each other to maintain 
the immune response.   
In summary, TLR2 and TLR4 serve as the most significant receptors for SAA to induce the 
production of proinflammatory mediators. IL-6, IL-1β and MCP-1 are the major SAA-
stimulated cytokines. The intracellular signaling pathway after TLR2/TLR4 activation 
includes the receptor adaptor MyD88, protein kinase MAPK and transcription factor NF-κB 
(Table 1). NLRP3-caspase-1 can also be activated by SAA and mediates IL-1β release48. 
The interconnections between these signaling pathways and SAA-induced cytokines have 





1.5 ROS and NO induced by SAA 
ROS are a group of reactive chemical species containing oxygen that are generated through 
NADPH oxidase 2 (NOX2)-dependent and independent pathways. Depending on the source, 
ROS can be classified as mitochondrial-derived ROS and intracellular-generated ROS. 
Among all the ROS forms (including hydrogen peroxide, hydroxyl radicals, hypochlorous acid, 
anion hypochlorite, and superoxide anion radical), superoxide anion radical is a short-lived 
but key precursor of other ROS forms in cells75. Classically, ROS are considered host 
defense molecules released by neutrophils to kill pathogens such as bacteria. In addition, 
ROS can toxic to the cell. For instance, hydroxyl radicals remove hydrogen atoms from lipids, 
nucleic acids, and proteins, which yields the formation of reactive radicals and finally results 
in cell death. This cytotoxicity contributes to the pathological processes of atherosclerosis, 
diabetes and inflammation76,77. In recent years, numerous studies have demonstrated that 
ROS are not only the products of cellular reactions but are also mediators for multiple cell 
signal transductions78, such as the activation of NLRP3 inflammasomes79.  
SAA can induce both intracellular ROS and mitochondrial ROS69,80. However, the sources 
of these ROS were shown to be controversial in two studies. In fibroblasts, the SAA-induced 
ROS was NADPH dependent80, whereas in another study in macrophages, 
diphenyliodonium (DPI) (NADPH inhibitor) promoted more ROS than inhibited ROS 
production69. The SAA-induced ROS were found to participate in NLRP3 activation68,69. 
Other biofunctions of SAA-induced ROS need to be explored. 
Nitric oxide (NO) also belongs to free radicals and is a critical cell signaling molecule. The 
three NO synthase (NOS) systems, according to the original tissues in which they were first 
described, are named endothelial NOS (eNOS), neuronal NOS (nNOS) and inducible NOS 
(iNOS). NO generated from different NO synthases can have distinct effects. For example, 
eNOS-generated NO plays a protective role in the cardiovascular system by inhibiting 
smooth muscle cell proliferation, endothelial apoptosis and cell adhesion, and suppressing 
platelet aggregation81. As its name suggests, iNOS is inducible and can regulate the immune 
response82. The upregulation of iNOS in macrophages contributes to acute lung injury, 
insulin resistance, intestinal neuron damage, and tumor cell survival83-86. iNOS also plays a 





and promoting carotid plaque vulnerability via NF-κB activating88. Interestingly, SAA 
decreases eNOS in human aortic endothelial cells89 but upregulates iNOS in murine 
macrophages90. The reduced eNOS and increased iNOS can both lead to adverse outcomes 
of the cardiovascular system. Thus, there is an outstanding necessity to investigate 
mechanisms for SAA-induced NO production.  
1.6 Blood purification methods and their ability to remove solutes 
Considering the proinflammatory property of SAA and the association found between this 
protein and CKD2,91, remove SAA from bloodstream might be a promising therapy option for 
CKD patients. 
Different blood purification methods designed to remove certain substances from the blood 
are available in the clinic. Hemodialysis (HD) and hemofiltration (HF) are the two major renal 
replacement therapies. HD is a diffusion method, in which the molecular movement of 
solutes is achieved by a concentration difference. The first generation of HD units had a 
good ability to remove low-molecular-weight uremic toxins such as urea and creatinine. After 
more medium- to high-molecular-weight uremic solutes were identified in CKD92, second 
generation materials such as high-flux membranes with increased permeability were 
developed. The high-flux membrane has a better dialysis adequacy which can remove 
substance with molecular mass in the range of 2-50 kD (compared to 2-15 kD for low-flux or 
general membranes)93. However, no consistent conclusion has been reached regarding the 
benefit of this new material in different clinical settings. During HF treatment, medium-
molecular weight solutes are removed by the movement of fluid in response to an osmotic 
force. This therapy is more frequently applied in acute kidney failure patients and is usually 
combined with HD, which is referred to as hemodiafiltration (HDF). Standard HF has 
limitations in the removal of inflammatory toxins94. By increasing plasma-water exchanges, 
high-volume HF (HVHF) can remove inflammatory mediators from plasma. However, no 
improvement in survival was found in sepsis patients receiving HVHF treatment when 
compared to those receiving standard dialysis95. Based on the ability of HF to remove middle-
molecular-weight solutes, a high cut-off (HCO) membrane has been developed to eliminate 
inflammatory mediators. The HCO membrane shows the potential to remove cytokines 





duration, and molecular weight cut-off need to be further addressed96. Unlike the membrane-
based technology applied in HD and HF, hemoadsorption places sorbents in direct contact 
with blood and has the ability to adsorb high-molecular-weight substances. CytoSorbTM 
adsorber is a kind of biocompatible bead designed to remove pro- and anti-inflammatory 
mediators with molecular weight of 5-60 kDa. Studies have shown a notable reduction of in 
cytokines such as IL-6, IL-8, TNF-α, and CCL2 and pathogen-associated molecular patterns 
within several hours of CytoSorbTM adsorber treatment97,98. However, none of the above 
studies have reported the effect on SAA level during treatment. 
1.7 Aim of the study  
Given the critical role of SAA in the sustained inflammatory reaction that contributes to the 
mortality and cardiovascular complications of CKD patients, it is necessary to explore the 
detailed mechanisms behind this. In atherosclerosis, macrophages are activated by danger 
ligands such as oxidized LDL (oxLDL), which consequently leads to the production of 
proinflammatory cytokines that results in disease progression99. Elevated SAA can also be 
a danger ligand for macrophages, but the subsequent reactions are still not clear. Therefore, 
there are two aims in the first part of this study. One is to confirm the ability of SAA to induce 
proinflammatory mediators including IL-1β, IL-6, MCP-1, nitrite production and ROS in 
macrophages. Another is to investigate signaling pathways for these SAA-induced reactions. 
Since TLR2 and TLR4 serve as the best receptors for SAA, these two receptors were 
included in this study. The NLRP3 inflammasome has been found to participate in SAA-
induced IL-1β release, but no information is available regarding the role of the NLRP3 
inflammasome in the generation of other cytokines. Therefore, the NLRP3 inflammasome 
was investigated as the intracellular signaling pathway for SAA-mediated cytokine 
production. 
Our previous research has demonstrated that the SAA concentration can reach 300 µg/ml 
in dialysis patients. How to remove SAA from the blood is a completely unknown question. 
The molecular weight of SAA is 11.4-12.5 kDa, which means that HDL-free SAA can be 
eliminated by HD and HF. After the association of SAA with HDL in the circulation, the 





SAA in regular dialysis. The purpose of the second part of this study is to explore methods 
for removing SAA from the bloodstream.




2 Materials and methods 
 
2.1 Manufacturer information on regents, devices and software 
 
Table 2 Materials for cell culture 
 
 
Table 3 Agonists and antagonists 
 
Chemical formulas: TAK-242, C₁₅H₁₇ClFNO₄S; CU CPT22, C19H22O7.H2O; MCC950, 
C20H24N2O5S 
  
Medium and materials for cell culture Manufacturer 
Dulbecco’s modified Eagle’s medium (DMEM) Biochrom AG, Berlin, Germany 
Fetal bovine serum (FBS)  Biochrom AG, Berlin, Germany 
L-glutamine Biochrom AG, Berlin, Germany 
Penicillin/streptomycin Biochrom AG, Berlin, Germany 
Phorbol 12-myristate 13-acetate (PMA) Sigma, MO, USA 
Roswell Park Memorial Institute (RPMI) 1640 Biochrom AG, Berlin, Germany 
Receptors Agonists Manufacturer Antagonists Manufacturer 










Toll-like receptor 2 
(TLR2) 
- - CU CPT22 Tocris, MO, USA 
NLRP3 
inflammasome 












Table 4 Regents for qRT-PCR 
 
 









QIAGEN, Venlo, Netherlands ß-mercaptoethanol 
RNeasy Kit 
cDNA synthesis 
RT-Buffer ThermoFisher Scientific, USA 
dNTP’s ThermoFisher Scientific, USA 
Random Primer ThermoFisher Scientific, USA 
MultiScribe RT Bio-Rad, CA, USA 
PCR 
iQ SYBR Green Supermix Bio-Rad, CA, USA 
Primers TIB Molbiol, Berlin, Germany 
Regents Manufacturer 
CellTiter 96® Aqueous One Solution Cell 
Proliferation Assay 
Promega, Madison, USA 
CytoTox-Glo™ Cytotoxicity assay Promega, Madison, USA 
Diagnostic reagent for lipids and lipoproteins 
DiaSys, Diagnostic Systems GmbH, 
Germany 
DiaSys Diagnostic Systems GmbH, Holzheim, Germany 
Griess Reagent System Promega, Madison, USA 
Human serum amyloid A (Hu SAA) ELISA Kit ThermoFisher Scientific, USA 
MILLIPLEX® MAP Human Cytokine/Chemokine 
Magnetic Bead Panel 
Merck KGaA, Darmstadt, Germany 
NP40 cell lysis buffer Invitrogen, CA, USA 
Pierce™ BCA Protein Assay ThermoFisher Scientific, USA 




Table 6 Materials used in CytoSorbTM experiment 
 
 
Table 7 Devices and software 
 
 
2.2 Cell culture 
2.2.1 THP-1 cell culture and differentiation 
THP-1 cells were purchased from American Type Culture Collection (Manassas, 
VA, USA) and were stored in cryovials in liquid nitrogen in 90% FBS and 10% 
dimethyl sulfoxide (DMSO). Cells were defrosted with a fast warm up in a 37°C 
water bath until just defrosted. Then, the cells were quickly transferred into 
prewarmed media and centrifuged at 2,000 rpm for 5 min. Cells were cultured in 
RPMI-1640 (2 mM L-glucose) medium supplemented with 10% FBS and 1% 
antibiotic (penicillin/streptomycin) in 75 cm2 culture flasks at 37°C with 5% CO2. 
Cell density was maintained at approximately 1 × 106 cells/ml during culture. THP-
Materials Manufacturer 
CytoSorbTM adsorber CytoSorbents Europe GmbH, Berlin, Germany 
Heidelberger Extension Fresenius Kabi AG, Germany 
Pump tube  IDEX Health & Science, Germany 
Pump ISMATEC, Germany 
1 ml Column SUPELCO, Germany 
595 Filter paper GE Healthcare Life Science, Germany 













statistical software v6.0 
GraphPad, CA, 
USA 
Bio-Plex 100 Bio-Rad, CA, USA 
BioRad CFX Manager 
Software 3.1  
Bio-Rad, CA, 
USA 
Bio-Rad T100 and 
C1000 Thermal Cycler 









1 monocytes were differentiated into macrophage-like cells by treatment with 200 
µg/ml PMA for 24 h. 
2.2.2 RAW 264.7 cell culture 
The company source, the storage conditions, and the cell defrosting procedure are 
all the same as for THP-1 cells. DMEM medium (4.5 g/L D-glucose) supplemented 
with 10% FBS and 1% antibiotic (penicillin/streptomycin) was used for RAW 264.7 
cell culture. The incubator conditions were also set as 37°C with 5% CO2. Cells 
were split when they reached approximately 80% confluency. Cells were dislodged 
from the flasks by using a cell scraper. 
2.3 Quantitative RT-PCR 
qRT-PCR was performed to quantify TLR2 and TLR4 mRNA levels. THP-1 
monocytes and macrophages were serum starved in flasks for 24 h, and the total 
mRNA was extracted from the cells using the RNeasy Kit from Qiagen according 
to the manufacturer’s protocol. The procedure was run by QiaCube or by hand. 
Briefly, cells were washed by twice ice-cold PBS, and then groups of 1 × 106 cells 
were lysed in 350 µl RLT Buffer with 1% β-mercaptoethanol. After cryopreservation 
at -80°C for 2 h, the mRNA was extracted by several short centrifugations after 
each kit was added to the RNeasy spin column, and then the mRNA was washed 
down from spin columns with 50 µl RNase-free water into collection tubes. 
Afterward, cDNA was synthesized from mRNA using random primers. The reaction 
conditions were 10 min at 25°C, and 2 h at 37°C. Finally, each target and 
housekeeper gene was quantified by PCR using designed primers (Table 8). The 
reaction volume in each well (384 well-plate) was 10 µl, with 3 µl (4.5 µg) cDNA, 
0.8 µl of primers (0.4 µl forward and 0.4 µl reverse 10 µM primers), and 6.2 µl iQ 
SYBR Green Supermix (5 µl Supermix and 1.2 µl water). The PCR conditions were 
as follows: initial denaturation for 3 min at 95°C, denaturation for 15 sec at 95°C 
for 39 cycles, primer annealing for 15 sec at 60°C, and DNA extension for 1 min at 
72°C. Data were analyzed by Bio-Rad CFX Manager Software 3.1. The results 
were verified by running amplified cDNA on a 2% agarose gel. 
  




Table 8  Primers for PCR 




fwd: 5 -́ AAC CCC AAG GCC AAC CGC GAG AAG 
ATG ACC - 3  ́
415 
rev: 5 -́ GGT GAT GAC CTG GCC GTC AGG CAG 
CTC GTA - 3  ́
Human GAPDH 
fwd: 5 -́ CATGGGTGTGAACCATGAGAA - 3  ́
132 
rev: 5 -́ GGTCATGAGTCCTTCCACGAT - 3  ́
Human TLR2 
fwd: 5' - GGC CAG CAA ATT ACC TGT GT - 3' 
320 
rev: 5' - CTC CAG CTC CTG GAC CAT AA - 3' 
Human TLR4 
fwd: 5' - GGT GGG AAT GCT TTT TCA GA - 3' 
358 
rev: 5' - AAT TGC CAG CCA TTT TCA AG - 3' 
Fwd, forward primer; rev, reverse primer; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; 
TLR, Toll-like receptor.  
 
2.4 Assays 
2.4.1 BCA assay   
BCA Protein Assay is a method that combines the reduction of Cu2+ to Cu1+ by 
protein with the colorimetric detection using a reagent containing bicinchoninic acid. 
The reaction is shown in Figure 3. The working range for the standard protocol is 
20-2000 µg/ml protein. Samples with an estimated concentration higher than 1500 
µg/ml were prediluted with PBS. The test was run according to the protocol. 
Summarized as working reagent preparation (50 parts of BCA Reagent A with 1 
part of BCA Reagent B), samples and working reagent mixing, and a 30 min at 
37°C incubation. Finally, read plates at 560 nm. The results were calculated by 















2.4.2 Proliferation assay 
Cell proliferation was determined by CellTiter 96® Aqueous One Solution Cell 
Proliferation Assay (MTS), which is a colorimetric method for determining the 
number of viable cells. First, 0.5 × 105 cells/well of THP-1 macrophages were 
seeded in 96-well plates for 24 h with serum starvation first. Then, the cells were 
stimulated cells for 24 h with different concentrations of drugs. To summarize, next 
20 µl CellTiter One Solution Reagent was added into each well, the cells were 
incubated at 37°C and 5% CO2 for 30-60 min until the medium color turned 
between yellow and dark brown, and finally the absorbance at 490 nm was 
determined. The results were analyzed by normalizing absorbance to the control 
group and calculating the percentage of viable cells in stimulated groups.  
 




2.4.3 Cytotoxicity assay 
Cytotoxicity was detected by CytoTox-Glo™ Cytotoxicity assay. This assay uses 
luminescence to determine the number of dead cells in the cell population (Figure 
5). To optimize the results, assay sensitivity was determined beforehand using 
different densities of THP-1 macrophages. According to the sensitivity assay 
results, 5,000 cells/well of THP-1 macrophages in 96-well white-wall-clear-bottom 
plates were employed in this assay. The stimulation was the same as in the 
proliferation assay. Briefly, after adding 50 µl of Cytotoxicity assay reagent to each 
well and incubating the cells for 15 min at room temperature, the luminescence 
values were determined by a Mithras plate reader. Luminescence values obtained 




at this step represented the number of dead cells. Afterward, 50 µl cell lysis reagent 
(33 µg digitonin in 5 ml assay buffer) was added to each well, and the plate was 
shaken at 600 rpm for 15 min. The plate was then read for the second time. 
Luminescence values acquired from this step indicated the total cell number. The 
number of viable cells was calculated by the absorbance difference between the 
total cell and the dead cell measurements. The results were normalized to the 
control group to obtain the percentage of viable cells.   
 




2.4.4 Nitrite production detection 
Nitrite production was determined by Griess Reagent System, which is based on 
chemical reactions between NO2-, sulfanilamide, and N-1-
naphthylethylenediamine dihydrochloride (NED) under acidic conditions (Figure 6). 
The final chemical product has an azo-compound that can be detected by a 520-
550 nm filter. After 24 h of stimulation, 50 µl of supernatant from each well was 
collected after 10 min of centrifuge at 1,200 rpm at 4°C. The nitrite solution 
standard (100 µM) was set up at 6 serial 2-fold dilutions (50 µl/well) to generate a 
standard reference curve. Afterward, 50 µl of sulfanilamide solution was added to 
all experimental samples and standards. After incubating for 5-10 min at room 




temperature protected from light, 50 µl NED Solution was added to each well. Then, 
incubation for another 5-10 min was carried out at room temperature in the dark. 
Finally, absorbance values were obtained within 30 min at 540 nm. Nitrite 
production was calculated by adjusting to the standard curve.  
RAW 264.7 cells were seeded in 96-well plates and serum starved (DMEM without 
serum and phenol red, plus 1% glutamine and antibiotics) for 24 h before 
stimulation. The cell density for this experiment was 50,000 cells/well. 
  




2.4.5 ROS detection 
Intracellular oxidants were detected by dihydroethidium (DHE). DHE can form a 
red fluorescent product after reacting with the superoxide anion, with maximum 
excitation and emission peaks at 480-520 and 570-600 nm, respectively. After 
stimulation, the cells were washed with warm PBS once. Then, the plate was 
centrifuged for 5 min at 500 × g, PBS was aspirated and 100 µl DHE working 
solution (5 µM) was added to each well. After 90 min incubation at 37°C (protected 
from light), the plate was measured by a fluorescent plate reader using an 
excitation wavelength of 485-530 nm and an emission wavelength of 590-620 nm. 
Mitochondrial-derived ROS were measured using the MitoSOX Red fluorescent 
probe. This probe is similar to DHE in that it also reacts with superoxide anions but 
is specific for ROS production in the mitochondrial matrix. Cells were washed with 




warm PBS once after stimulation. Then the plate was centrifuged for 5 min at 500 
× g, PBS was aspirated and 100 µl MitoSOX Red working solution (5 µM) was 
added to each well. According to the manufacturer’s protocol, cells were incubated 
for 10 min at 37°C (protected from light). Finally, the plate was measured by a 
fluorescent plate reader at excitation/emission wavelengths of 485-530/590-620 
nm, respectively. 
2.4.6 LuminexTM assay 
MCP-1, IL-1β and IL-6 were detected by MILLIPLEX® MAP Human 
Cytokine/Chemokine Magnetic Bead Panel in a Bio-Plex 100 device, based on the 
LuminexTM xMAP® technology (Figure 7). THP-1 macrophages were seeded in 96-
well plates and serum starved for 24 h before treatment, and 10,000 cells/well were 
used in this experiment. After 24 h and 48 h of stimulation, the plates were briefly 
centrifuged, and the supernatants were collected in 1.5 ml tubes. The LuminexTM 
procedures were performed strictly according to the manufacturer’s instructions. 
Working standards were prepared for calculating cytokines concentrations, which 
were normalized to protein content. The protein content was determined from cell 
lysates. Briefly, cells were washed twice with PBS in the plate, lysed in 40 µl NP40 
cell lysis buffer per well for 10 min and transferred to tubes after resuspending at 
least 5 times. Protein concentration was determined by BCA assay after 
centrifugation of the cell lysates at 10,000 rpm for 10 min. Supernatant and cell 
lysates were harvested on the ice. The results were analyzed by Bio-Plex Manager 
software 4.1. 
The LuminexTM assay was also applied in SAA and C-reactive protein (CRP) 
measurements in the “Adsorption methods to remove SAA from plasma” 


































2.4.7 Human serum amyloid A ELISA assay 
Serum amyloid A was assessed by human serum amyloid A (Hu SAA) enzyme-
linked immunosorbent assay (ELISA) kit which is a solid-phase sandwich enzyme-
linked immunosorbent assay. The test range was 0-600 ng/ml. Samples were 
diluted by a factor from 10~10000 before measurements. The ELISA assay was 
run according to the manufacturer’s instructions. Eight concentrations of standard 
from 0 to 600 ng/ml were prepared for calculating the reference standard curve. 
Since the standard supplied by the manufacturer was human native SAA, but the 
Figure 7 LuminexTM assay principle 
(https://www.rndsystems.com/resources/technical/luminex-assay-principle) 
Step 1: Color-coated polystyrene beads are mixed with the antibodies pre-coated by analyte-
specific capture. The sample is added to this mixture. The antibodies bind to the corresponding 
analyte. Step 2: Detection antibodies specific to the analytes are added to form an antibody-antigen 
sandwich. Then phycoerythrin (PE)-conjugated streptavidin is added. Streptavidin binds to 
biotinylated detection antibodies. Step 3: Beads are read on a dual-laser flow-based detection 
instrument. One laser classifies the bead and determines the analyte. Another laser quantifies the 
analyte by determining the magnitude of the PE-derived signal. 




SAA used in our research was a recombinant one, the results were adjusted to the 
0 h SAA concentration.    
2.4.8 Lipids and lipoprotein determination 
Triglycerides, cholesterol, phospholipids, HDL-C and LDL-C were all determined 
by methods based on an enzymatic photometric assay. Principles for those assays 
are shown in Table 9. 
2.5 Adsorption methods to remove SAA from plasma 
To explore methods to remove SAA from the blood, a mini plasma adsorption 
system was established by our group. CytoSorbTM adsorber and another 
adsorbent beads made by novel material were used in this experiment. 
2.5.1 Principle and design of the experiment 
Human plasma was isolated from whole blood collected in EDTA-treated tubes 
from healthy volunteers by centrifugation for 15 min at 2,000 × g. The main purpose 
of this experiment was to determine the ability of the materials to remove SAA from 
plasma. Thus, 31.25 µg/ml recombinant SAA was added into 10 ml serum. The 
control sample was serum from the same subject but without the addition of SAA. 
Detailed experimental settings are included in the next section. The pump running 
speed was set as 9. Samples from 0 h, 4 h, 24 h, 48 h and 72 h treatment points 
were collected for further measurements. Bead columns were replaced by new 
columns at 24 h intervals. SAA, lipids, lipoproteins, CRP, and total protein were all 
measured. The system without adsorbent beads was first tested to exclude the 
non-specific binding of the system, by running samples in the system without 
beads for 72 h. 
2.5.2 Experimental settings 
To construct the mini plasma adsorption system (Figure 8 A) included the following 
steps. During system construction, the fluid outlet tubing was ensured to be 
sufficiently long to reach the bottom of the tube. Materials and devices are shown 
in Figure 8 B. 
• Prepare beads solution with PBS and adsorbent beads.  




• Cut filter paper size to fit in the bead column.  
• Put the filter paper into one end of the reaction vessel. 
• Fill the reaction vessel with beads solution, which is the adsorbent bead 
column in the system. Remove all the PBS in the column by a syringe, to 
avoid sample dilution during treatment.  
• Connect the system with infusion extension tube. 
• Run the system as in Figure 8 A without a bead column to fill the system 
with fluid and ensure a good connection in the whole system.  
• Run the system with bead column.  
• The sample is running in the direction as shown in Figure 8 A, and the 
column is kept vertical during treatment. The filter paper side is the outlet 
end of the column is always at the bottom to ensure that adsorbent beads 










Statistical analysis was performed using GraphPad Prism statistical software v6.0 
(GraphPad, CA, USA). Data are presented as the means ± SEM, unless otherwise 
Figure 8 Diagram (A) and materials (B) applied in the mini plasma adsorption system 
1. pliers, 2. scissors, 3. 15 ml tube, 4. 1 ml column tube, 5. infusion extension tube, 6. pump tubing 


















indicated. A two-tailed paired t-test was applied for detecting differences between 
two groups (untreated vs. treated or SAA vs. SAA + antagonists) in nitrite 
production and cytokine detection experiments. Significance was accepted at P < 
0.05.
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Assay reaction Explanation 
LDL 
 
1) LDL-C is selectively protected while non-LDL-
lipoproteins are enzymatically processed. 
2) LDL-C is released and selectively determined.  
HDL 
 
1) Reagent 1 including antigen-antibody complexes 
with LDL, VLDL and chylomicrons can protect these 
lipoproteins from the enzyme. 




Triglycerides levels are determined after an enzymatic 
reaction by lipoprotein lipase. Finally, the indicator 
quinoneimine is generated from aminoantipyrine and 4-
chlorophenol by hydrogen peroxide under the catalytic 
action of peroxidase. The catalysts are all included in 
one reagent. 








Cholesterol is measured after enzymatic hydrolysis and 
oxidation. The colorimetric indicator is quinoneimine. 





1) Phospholipids are tested after enzymatic hydrolysis 
and oxidation. 
2) The colorimetric indicator is chinone dye. 
Triglycerides 
 
Triglycerides levels are determined after an enzymatic 
reaction by lipoprotein lipase. Ultimately, the indicator 
quinoneimine is generated from aminoantipyrine and 4-
chlorophenol by hydrogen peroxide under the catalytic 
action of peroxidase. The catalysts are all included in one 
reagent. 






3.1 IL-6, IL-1β and MCP-1 detection in THP-1 macrophages 
SAA stimulates the production of proinflammatory cytokines in various cell types 
(Table 1) including macrophages. To assess this property, the levels of IL-6, IL-1β 
and MCP-1 were determined in SAA-stimulated THP-1 macrophages. The SAA-
induced cytokines levels were compared to those induced by LPS, which is a class 
PAMP. 
Both LPS and SAA could stimulate IL-6, IL-1β and MCP-1 production in THP-1 
macrophages (Figure 9 A, B, C), but the cytokine levels were higher in SAA-treated 
cells. During the stimulation, all three cytokines were secreted in a time-response 
manner, especially IL-6. Since pro-IL-1β needs to be cleaved and then released 
from the cell, the intracellular IL-1β level was also determined and compared to 
the level in the supernatant, which showed that the intracellular IL-1β level was 
much higher than that in the supernatant, especially in SAA-stimulated cells 
(Figure 9 D).   
3.2 TLR2 and TLR4 expression levels in THP-1 monocytes and macrophages 
SAA binds to various receptors. Our team has confirmed the role of FPR2 in SAA-
mediated MPC-1 generation in vascular smooth muscle cells4. To better 
understand the proinflammatory properties of SAA, two other critical receptors, 
TLR2 and TLR4, were included in this study. Before the stimulation experiments, 
the expression levels of these two receptors were quantified in THP-1 cells 
(macrophages and monocytes) by qRT-PCR. The TLR2 and TLR4 mRNA levels 
were normalized to both housekeeper genes β-actin and GAPDH. According to 
Figure 10 A, TLR2 and TLR4 were both expressed in THP-1 monocytes and 
macrophages at comparable levels. The results were confirmed by running 






















Figure 9 IL-6, IL-1β and MCP-1 detection in SAA- and LPS-stimulated THP-1 macrophages 
IL-6 (A), IL-1β (B) and MCP-1 (C) were quantified in SAA- and LPS-stimulated THP-1 macrophages. 
Intracellular IL-1β levels in LPS- and SAA-stimulated cells were determined and compared to the 
levels in the supernatant (D). THP-1 macrophages were stimulated with 1 µg/ml SAA or 1 µg/ml LPS 
for 24 h and 48 h. No treatment in the control group. Data are presented as means ± SEM of three 
(IL-6 and IL-1β) or two (MCP-1) independent experiments. * P < 0.05 vs. control by Wilcoxon 



































































































1 0 0 0
2 0 0 0
3 0 0 0
4 0 0 0




































































































































T H P -1  m o n o c y te
T H P -1  m a c ro p h a g e
 
Figure 10 TLR2 and TLR4 expression levels in THP-1 monocytes and macrophages  
A: The relative normalized mRNA expression of TLR2 and TLR4 in THP-1 macrophages and 
monocytes measured by qRT-PCR. B: Agarose gel electrophoresis of TLR2, TLR4 and β-actin 
PCR products, 100 bp DNA ladder. Samples 3 and 4 were from THP-1 macrophages, and samples 







3.3 The role of TLR2 and TLR4 in SAA-induced IL-6, IL-1β and MCP-1 
secretion  
Both the time- and dose-dependent effects of antagonists were determined to 
better understand the role of TLR2 and TLR4 in SAA-mediated cytokine induction. 
Therefore, THP-1 macrophages were stimulated by SAA or SAA + antagonists (5 
µM and 10 µM) for 24 h or 48 h. The TLR4-specific antagonist TAK-242 and the 
TLR1/TLR2 heterodimer blocker CU CPT22 were used in this study.  
The results (Figure 11) showed that TAK-242, at a concentration of 10 µM, blocked 
SAA-induced IL-6, IL-1β and MCP-1 in both 24 h and 48 h stimulations, while CU 
CPT22 only significantly inhibited MCP-1 and 24 h-induced IL-6 but had no effect 
on SAA-stimulated IL-1β production. 
3.4 The NLRP3 inflammasome inhibitor MCC950 decreases IL-1β but has no 
effect on IL-6 and MCP-1 secretion in SAA-stimulated THP-1 macrophages 
The NLRP3 inflammasome has been shown to be involved in a range of 
inflammatory conditions100 and to participate in the process of SAA-mediated IL-
1β production48. It has been reported that IL-1β can further induce IL-6 and MCP-
161,101, but these cytokines may also be secreted independently74. It is not clear 
whether SAA-induced IL-1β will further promote IL-6 and MCP-1 production. To 
answer this question, MCC950, an inhibitor that targets NLRP3 inflammasome 
activation but not priming, was employed in this experiment.  
THP-1 macrophages were treated with SAA and SAA plus different concentrations 
(0.1 µM and 1 µM) of MCC950 for 24 h and 48 h. As shown in Figure 12, MCC950 
decreased SAA-induced IL-1β in 24 h and 48 h stimulation in a dose-dependent 











































Figure 11 IL-6, IL-1β and MCP-1 detection in THP-1 macrophages co-stimulated with SAA 
and TAK-242, or CU CPT22 
IL-6 (A), IL-1β (B) and MCP-1 (C) were quantified in THP-1 macrophages that co-stimulated with 
SAA and TAK-242, or CU CPT22 for 24 h and 48 h. Cells in the SAA only group were treated with 
SAA (10 µg/ml). Cells in different doses of TAK-242 and CU CPT22 groups were co-stimulated with 
10 µg/ml SAA. Data are presented as the means ± SEM. N ≥ 3.  * P < 0.05 vs. SAA group by 







































































1 0 0 0
1 5 0 0






































































































1 0 0 0
1 5 0 0




































1 0 0 0
1 5 0 0
2 4 h
4 8 h

































3.5 Cell viability evaluation 
To exclude the effects on cell toxicity of antagonists used in this project. The toxic 
effects of CU CPT22, TAK-242 and MCC950 on THP-1 macrophages were tested. 
The proliferation assay was performed for a cytotoxicity screening. This assay 
detects cell metabolic activity rather than directly evaluating the drug’s cell toxicity. 
Thus, a cytotoxicity assay that determines the number of dead cells was also 
employed.  
Figure 12 IL-6, IL-1β and MCP-1 detection in SAA and SAA/MCC950 co-stimulated THP-1 
macrophages 
IL-6 (A), IL-1β (B) and MCP-1 (C) were detected SAA and SAA/MCC950 (0.1 µM and 1 µM) co-
stimulated THP-1 macrophages. Cells in the SAA group were only treated with SAA (10 µg/ml). 
Cells treated with different doses of MCC950 were co-stimulated with 10 µg/ml SAA. Data are 
presented as the means ± SEM. N ≥ 3. * P < 0.05 vs. the SAA group by Wilcoxon matched-pairs 
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THP-1 macrophages were stimulated with different concentrations (0.01 µM, 0.1 
µM, 1 µM, 10 µM, and 100 µM) of CU CPT22, TAK-242 and MCC950 plus 10 µg/ml 
SAA for 24 h and 48 h. The results of the cell proliferation assay and the cytotoxicity 
assay measuring cell viability were adjusted to the control group results. When co-
stimulated with 10 µg/ml SAA, both CU CPT22 and TAK-242 showed significant 
cell toxicity for THP-1 macrophages at concentration 100 µM, the cell viability was 
much lower than control or other treatment groups. At concentration 10 µM or lower, 
both CU CPT22 and TAK-242 had no apparent cell toxicity on THP-1 macrophages, 
the cell viability was from 80% to 100% (Table 10 and Table 11).  
In all MCC950 stimulations (also co-stimulated with 10 µg/ml SAA), the cell viability 
from both assays was higher than 90% after adjusted to the control group. Which 
means that MCC950 had no significant cell toxicity on THP-1 macrophages even 
at a concentration of 100 µM (Table 12). The concentrations of each antagonist in 
bold type in the following tables were applied in this study. 





Proliferation assay Cytotoxicity assay 
24 h  48 h 24 h  48 h 
Cell viability   Cell viability   Cell viability  Dead cell  Cell viability  Dead cell  
0 0 100% 100% 100% 9% 100% 12% 
0.01 10 102% 105% 95% 14% 81% 29% 
0.1 10 102% 115% 91% 17% 85% 26% 
1 10 100% 122% 91% 17% 83% 27% 
10 10 87% 90% 93% 15% 90% 21% 
100 10 80% 85% 51% 54% 65% 43% 
 





Proliferation assay Cytotoxicity assay 
24 h  48 h 24 h  48 h 
Cell viability   Cell viability   Cell viability  Dead cell  Cell viability  Dead cell  
0 0 100% 100% 100% 9% 100% 12% 
0.01 10 92% 109% 90% 18% 81% 29% 
0.1 10 98% 97% 86% 21% 82% 28% 
1 10 105% 137% 89% 19% 84% 26% 
10 10 91% 134% 90% 19% 93% 19% 









Proliferation assay Cytotoxicity assay 
24 h  48 h 24 h  48 h 
Cell viability   Cell viability   Cell viability  Dead cell  Cell viability  Dead cell  
0 0 100% 100% 100% 7% 100% 7% 
0.01 10 152% 175% 97% 9% 95% 11% 
0.1 10 146% 171% 98% 10% 96% 11% 
1 10 149% 185% 98% 9% 95% 12% 
10 10 152% 173% 97% 10% 95% 12% 
100 10 103% 109% 97% 12% 92% 15% 
 
3.6 Nitrite production detection 
NO is a free radical and a critical cell signaling molecule that plays an essential 
role in diverse pathophysiological processes such as the endothelial dysfunction102, 
macrophage proliferation103 and immune responses82. Therefore, this section aims 
to investigate the ability of SAA to induce NO production and the pathway involved 
in this process. Nitrite production levels were first quantified in SAA- and LPS-
stimulated RAW 264.7 cells and THP-1 cells. However, no production was 
detected in THP-1 monocytes and macrophages (data not shown). Therefore, only 
RAW 264.7 cells were employed in the signaling pathway detection. 
3.6.1 Nitrite production detection in SAA- and LPS-stimulated RAW 264.7 
cells  
RAW 264.7 cells were treated with different concentrations (0.1 µg/ml, 1 µg/ml and 
10 µg/ml) of LPS and SAA. After a 24 h stimulation, a dose-response increase in 
nitrite production was found in SAA- and LPS-treated RAW 264.7 cells (Figure 13 
A). Results were from one stimulation and no statistical significance was found 
between the control and LPS- or SAA-treated cells. When compared results from 
6 stimulations, 1 µg/ml LPS or 10 µg/ml SAA promoted significantly increased 
nitrite production in RAW 264.7 cells (Figure 13 B).  





















3.6.2 The role of TLR2, TLR4 and NLRP3 in SAA-stimulated nitrite production 
in RAW 264.7 cells 
According to previous studies, TLRs play essential roles in NO upregulation104,105. 
Therefore, the role TLR2 and TLR4 in SAA-induced NO production was 
determined in this section. After 24 h and 48 h stimulation, both TLR2 and TLR4 
antagonists of significantly inhibited of SAA-induced nitrite production in RAW 
264.7 cells (Figure 14).  
In addition to TLR activation, cytokines such as IL-1β can also trigger iNOS gene 
transcription106. Therefore, the NLRP3 inflammasome pathway was also tested 
here. As shown in the previous section, 1 µM MCC950 remarkably decreased 
SAA-induced IL-1β levels (Figure 12), but this inhibitor did not show any effect on 
the SAA-stimulated nitrite production (Figure 14). 
  
Figure 13 Nitrite production detection in SAA- and LPS-stimulated RAW 264.7 cells  
A: RAW 264.7 cells were stimulated with different concentrations (0.1 µg/ml, 1 µg/ml and 10 µg/ml) 
of LPS and SAA for 24 h. A dose-response increase in nitrite production was found in SAA- and 
LPS-treated RAW 264.7 cells. No treatment in the control group. Data are presented as the means 
± SEM of triplicated wells. LPS and SAA groups were compared to control group. No statistical 
significance was found. B: RAW 264.7 cells were stimulated with 1 µg/ml LPS or 10 µg/ml SAA 
for 24h and 48h. Data are presented as the means ± SEM. N ≥ 3. * P < 0.05 vs. the control group 































































































3.7 ROS detection 
ROS are a group of reactive chemical molecules that can be toxic to the cell and 
contribute to the pathological processes of atherosclerosis76. Furthermore, ROS 
participate in multiple cell signaling pathways78 such as NLRP3 activation79. ROS 
are generated from two major sites in the cell and can be classified as intracellular 
ROS and mitochondrial ROS. These ROS might play distinct roles during cell 
signaling pathway activation. Therefore, both mitochondrial-derived ROS and 
intracellular generated ROS were detected in RAW 264.7 cells and THP-1 cells 
after the LPS and SAA stimulation.  
3.7.1 SAA promotes intracellular ROS in monocytes and macrophages 
Intracellular ROS were detected at 2 h, 4 h, 8 h, and 24 h treatment time points. 
The ROS level in SAA- or LPS-treated myeloid cells peaked at 2 h to 8 h and 
decreased afterward. Thus, Figure 15 only shows the ROS level in the early 
stimulation time points. At the same concentration, the ROS levels were higher in 
SAA-treated cells than LPS-treated control cells. No statistical significance was 
detected, which might be due to the limited number of test samples. 
Figure 14 Nitrite production measurement in RAW 264.7 cells co-stimulated with SAA and 
TAK-242, CU CPT22, or MCC950 
Nitrite production was detected in RAW 264.7 cells that stimulated with SAA (1 µg/ml) with or 
without TAK-242 (10 µM) or CU CPT22 (10 µM) (A) or  MCC950 (1 µM) (B) for 24 h and 48 h. Data 
are presented as the means ± SEM of 3 independent experiments. Co-stimulated groups were 
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3.7.2 SAA promotes mitochondrial ROS production in RAW 264.7 cells 
At the 2 h, 4 h, 8 h, and 24 h treatment time points, no mitochondrial ROS was 
detected in SAA- or LPS-treated THP-1 cells (data not shown), while mitochondrial 
ROS increased in both SAA- and LPS-treated RAW 264.7 cells after 24 h (Figure 
16). The 24 h stimulated mitochondrial ROS also seemed higher in the SAA group 





















Figure 15 Intracellular ROS detection in LPS- and SAA-stimulated cells 
RAW 264.7 cells, THP-1 monocytes and THP-1 macrophages were treated with 1 µg/ml SAA or 1 
µg/ml LPS. No treatment of cells in the control group. N ≥ 3. Data are presented as the means ± SEM 
of fluorescence values.  
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3.8 Experimental setting for SAA adsorption 
The previous sections verified the proinflammatory properties of SAA. These 
properties partially explain the association found between elevated SAA and 
complications in CKD patients. Regular renal replacement treatment can barely 
remove SAA. Therefore, the purpose of this section is to explore methods to 
remove SAA from the circulation. A mini plasma adsorption system was 
established to evaluate the adsorption of CytoSorbTM adsorber and another novel 
material. The procedure is shown in the Methods section in Figure 8. During the 
blood purification, one problem is that some “good” substances such as albumin 
will be lost as well. To test the adsorption of those materials, protein, triglycerides, 
total cholesterol, phospholipids, HDL-C, LDL-C and CRP were also detected.  
3.8.1 Nonspecific binding test  
To exclude the nonspecific binding, the system without adsorbent beads was 
tested first. Samples were run in the system without beads for 72 h, and 
substances were measured in the samples before and after the procedure. The 
results in Table 13 show that after the 72 h, no apparent adsorption of the tested 
substances by this system (without adsorbent beads) was found. 
  
Figure 16 Mitochondrial ROS detection in LPS- or SAA-stimulated RAW 264.7 cells 
RAW 264.7 cells were treated with 1 µg/ml SAA or 1 µg/ml LPS for 24 h. No treatment of cells in 
the control group. N ≥ 3. Data are presented as the means ± SEM of fluorescence values.  * P < 




Table 13 System adsorption test 
 Serum + SAA Serum 
 
Average ± SD  
(reduced concentration) N 
Average ± SD  
(reduced concentration) N 
SAA concentration (µg/ml) -6.83 ± 11.92 2 -0.10 ± 0.69 2 
Protein (mg/ml) -3.60 ± 0.14 2 -0.91 ± 3.59 2 
HDL-C[mg/dl] 11.24 ± 10.75 2 4.88 ± 1.45 2 
LDL-C [mg/dl] 5.71 ± 7.44 2 21.38 1 
Triglycerides [mg/dl] -8.10 ± 20.55 2 -4.06 ± 1.29 2 
Cholesterol [mg/dl] -2.38 ± 6.14 2 -0.83 ± 7.57 2 
Phospholipids [mg/dl] -2.83 ± 16.28 2 8.49 ± 2.72 2 
CRP concentration (µg/ml) 0.15 1 -0.79 1 
Note: Samples were divided into two equal portions, which were mixed with or without additional 
SAA. The samples were run in the system without adsorbent bead for 72 h. Data are presented as 
the means ± SD of the reduced concentration after 72 h of running two independent tests. SAA, 
serum amyloid A; HDL-C, high-density-lipoprotein cholesterol; LDL-C, low density lipoprotein 
cholesterol; CRP, C-reactive protein. 
 
3.8.2 CytoSorbTM adsorber evaluation 
CytoSorbTM adsorber are biocompatible beads designed to remove pro- and anti-
inflammatory mediators between a molecular weight of 5-60 kDa. In previous 
studies, CytoSorbTM adsorber has shown a good ability to reduce cytokines97,98. 
However, there are no available data on CytoSorbTM adsorber removing SAA.  
To test the SAA adsorption, 20 ml serum was divided into two equal portions. A 
total of 31.25 µg/ml recombined human SAA was added to one tube with 10 ml 
serum, which is the “serum + SAA” group in the following figures. Another tube 
with 10 ml serum without additional SAA is the “serum” group. Serum from both 
tubes was run in the mini plasma adsorption system simultaneously. Samples were 
collected after running for 0 h, 4 h, 24 h, 48 h and 72 h. Bead columns were 
replaced by new columns every 24 h. SAA, total protein, triglycerides, total 
cholesterol, phospholipids, HDL-C, LDL-C and CRP were determined in those 
samples. According to the results shown in the following figures, both recombinant 
SAA and natural SAA can be removed by CytoSorbTM adsorber (Figure 17). This 
adsorber also eliminates proteins, cholesterols and lipids. After 72 h treatment, 






























Figure 17 SAA, protein and CRP adsorption by CytosorbTM adsorber 
SAA (A), protein (B) and CRP (C) levels during CytosorbTM adsorber treatment. A total of 31.25 
µg/ml SAA was added to the serum in the serum + SAA group. Samples were collected after running 
them in the system for 0 h, 4 h, 24 h, 48 h, and 72 h. Bead columns were replaced by new ones 
every 24 h. Data are presented as the means ± SD of 3 independent experiments. 
 
Figure 18 Lipids adsorption by CytosorbTM adsorber 
Triglycerides (A) and phospholipids (B) levels during CytosorbTM adsorber treatment. A total of 
31.25 µg/ml SAA was added to the serum in the serum + SAA group. Samples were collected after 
running them in the system for 0 h, 4 h, 24 h, 48 h, and 72 h. Bead columns were replaced by new 
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3.9 Summary of results 
• SAA can induce IL-6, IL-1β and MCP-1 in THP-1 macrophages. 
• TLR4 participates in SAA-mediated IL-6, IL-1β and MCP-1 production in 
THP-1 macrophages. 
• TLR2 plays a role in the SAA-induced upregulation of MCP-1 and IL-6 but 
is not involved in SAA-induced IL-1β secretion. 
• SAA induces IL-1β through the NLRP3 inflammasome.  
• The SAA-promoted IL-6 and MCP-1 generation is not dependent on the 
NLRP3 inflammasome. 
Figure 19 Cholesterol adsorption by CytosorbTM adsorber 
HDL-C (A), LDL-C (B) and total cholesterol (C) levels during CytosorbTM adsorber treatment. A 
total of 31.25 µg/ml SAA was added to the serum in the serum + SAA group. Samples were 
collected after running them in the system for 0 h, 4 h, 24 h, 48 h, and 72 h. Bead columns were 
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• SAA can trigger nitrite production in RAW 264.7 cells but not in THP-1 cells. 
• Both TLR2 and TLR4 are involved in SAA-induced nitrite production in RAW 
264.7 cells.  
• The SAA-induced nitrite production is NLRP3 inflammasome independent. 
• SAA upregulates intracellular and mitochondrial ROS in myeloid cells.  





SAA was initially recognized as a biomarker for rheumatic diseases107. At the same 
time, this protein was found to be associated with HDL and was named apoSAA108. 
During the first decades, similar to CRP, SAA was only considered an acute phase 
reaction protein and a biomarker for inflammatory diseases. However, more 
evidence in the subsequent studies indicated that SAA is an immunologically 
active protein. For instance, SAA can induce the production of numerous cytokines 
via distinct receptors in different cells (Table 1) including macrophages. Since 
macrophages play a fundamental role in atherosclerosis, the SAA-mediated 
cytokine production in this cell type might be a remarkable reason for the 
development of this disease. Therefore, the first part of this study investigated the 
signaling pathway for SAA promoting the production of inflammatory mediators in 
macrophages, especially IL-1β, IL-6, MCP-1, nitrite production and ROS. 
Moreover, our previous work demonstrated increased SAA levels in CKD patients 
from dialysis units, which suggests a low efficiency of SAA removal by regular 
dialysis4. The proinflammatory property of SAA combined with this elevated level 
provide an explanation for the association found between SAA levels and 
cardiovascular complications in CKD patients. Accordingly, this study also 
explored methods for removing SAA from the bloodstream. 
4.1 Proinflammatory cytokines from SAA-stimulated macrophages 
Similar to previous reports, a significant increase in IL-1β, IL-6 and MCP-1 was 
detected in SAA-stimulated cells, which verified the cytokine-inducing property of 
SAA in human macrophages. 
An interesting finding in this study is that the recombinant SAA used in this study 
mediates higher levels of IL-1β, IL-6 and MCP-1 secretion when compared to LPS. 
Two major reasons might be responsible for this outcome. First, LPS is a TLR4-
specific agonist, whereas SAA is a ligand for multiple receptors (Table 1). The 
simultaneous activation of several receptors might lead to higher levels of 
cytokines. Another probable cause is the recombinant SAA that is a hybrid 





this SAA has a more potent capability of inducing cytokines compared to the 
purified natural SAA109. The proinflammatory properties of purified HDL-
disassociated and HDL-associated SAA has been demonstrated by our lab and 
other research teams as well4-6. Moreover, the concentration (1 µg/ml) of LPS 
applied in this study was even higher than the level in sepsis patients 
(approximately 0.5 µg/ml)110, while the concentration of SAA (1 µg/ml) used in this 
study was much lower than that in sepsis patients (up to 1 mg/ml). This 
concentration is also below the level in CKD patients (approximately 10-30 µg/ml). 
All these results suggest that the sustained elevated SAA in patients is an 
inflammatory mediator rather than just an acute phase reaction protein.  
Another observation that needs to be discussed here is that SAA cannot efficiently 
induce the release of IL-1β from THP-1 macrophages. Less than 1/10 of 
intracellular IL-1β was released into the supernatant in SAA-stimulated cells. 
According to previous studies, unlike LPS, which only upregulates pro-IL-1β but 
cannot induce the release of the mature cytokine111, SAA can independently 
promote IL-1β release48,68. In this study, the supernatant/intracellular IL-1β ratio 
was even lower in SAA-treated cells when compared to LPS-stimulated cells. This 
means that, SAA cannot readily promote the release of IL-1β. The activation of the 
NLRP3 inflammasome plays a central role in IL-1β maturation. The issue regarding 
activators for NLRP3 will be discussed in the next section. 
4.2  SAA-induced IL-1β is TLR4- and NLRP3 inflammasome-dependent 
This study found that SAA promotes IL-1β release through TLR4 in human 
macrophages. However, in both HeLa cells112 and mouse macrophages113, TLR2 
rather than TLR4 mediates SAA-mediated release of IL-1β. In keratinocytes, 
antibodies for TLR2 and TLR4 both downregulate IL-1β expression48. Our results 
have shown that the expression levels of TLR2 and TLR4 are comparable in THP-
1 macrophages, which excludes the possibility that the low expression of TLR2 
may lead to the negative finding in TLR2 antagonist treatment. Diverse cell types 





results. Since data from identical experimental settings are not available, our 
results need to be confirmed in future investigations.  
It has been reported that SAA stimulates IL-1β secretion via NLRP3 
inflammasome-caspase-149,68. MCC950 also blocks SAA-induced IL-1β in this 
study. MCC950 is a highly specific inhibitor of both canonical and noncanonical 
activation of the NLRP3 inflammasome114. The mechanism for this blockade is still 
not clear. Until now, we only knew that MCC950 neither suppresses NLRP3 
priming nor interrupts the NLRP3 and ASC interaction but targets NLRP3 
directly114. With a concentration of 1 µM, MCC950 nearly entirely abrogates the 
LPS-induced IL-1β114,115, but this inhibitor only partially blocks SAA-induced IL-1β 
in our experiments. One possible reason for this discrepancy is that alternative 
signaling pathways might exist for SAA mediating IL-1β maturation. IL-1β can be 
processed through an NLRP3 inflammasome-independent way67. For instance, an 
enzyme called proteinase 3 can also facilitate IL-1β maturation116. Another 
possible cause is the pro-IL-1β was released into the supernatant. The antibody 
used in LuminexTM assay cannot differentiate between pro-IL-1β and mature IL-1β. 
A certain percentage of the detected IL-1β in the supernatant might be pro-IL-1β. 
Other measurements, such as Western blotting, may help to further interpret this 
issue. On the other hand, MCC950 still blocks major SAA-induced IL-1β. Since the 
NLRP3 inflammasome needs to be activated to process IL-1β secretion, the 
activators should be present in SAA-stimulated cells. An ATP gated receptor, P2X7, 
has been found to be involved in SAA-mediated NLRP3 inflammasome activation49. 
However, this study did not find any ATP released from cells after SAA 
stimulation49. Intracellular IL-1β (pro-IL-1β) was not determined in previous 
studies48,68. The mechanism of SAA-induced NLRP3 inflammasome activation is 
still unknown. In patients with elevated SAA such as CKD patients, activators of 
the NLRP3 inflammasome can be frequently found, e.g., electrolyte imbalance and 
increased ROS. These activators are very likely to release SAA-upregulated 





4.3  SAA promotes IL-6 generation through TLR2 and TLR4, but in an NLRP3 
inflammasome-independent way 
This study shows that SAA mediates IL-6 generation in human macrophages 
through TLR2 and TLR4, whereas a TLR4 antagonist seemed more efficient at 
suppressing SAA-induced IL-6. Both TLR2 and TLR4 have been found to mediate 
SAA-induced IL-636,44,51,52. Moreover, other SAA receptors, SR-BI, RAGE and 
FPR2, have also been investigated, but these receptors did not mediate SAA-
induced IL-6 secretion in human primary chondrocytes51.  
In addition to TLRs ligands, other mediators such as IL-1β, TNF-α, ROS, and 
prostaglandins, can also promote IL-6 gene transcription117. In an earlier study, an 
IL-1β-deficient mouse model showed reduced IL-6 production61, which suggested 
a role for IL-1β in IL-6 generation. Signaling pathway studies have revealed that 
IL-1β mediates IL-6 generation through MAPK, AP-1 and NF-κB118,119. MCC950 
also suppressed IL-6 production in studies in vivo and in vitro114,115. Our results 
show that MCC950 has no effect on SAA regulation of IL-6. One possible reason 
for this is the relatively low IL-1β concentration in supernatants. Both SAA and IL-
1β can mediate IL-6 production via NF-κB. In this case, the IL-6 gene might have 
already been fully induced by SAA, and the subsequently released IL-1β could 
have no or few effects on IL-6 induction. The high intracellular IL-1β level and the 
comparable released IL-6 level both indicate a compelling case for SAA-mediated 
NF-κB activation. These results suggest that SAA itself can effectively promote IL-
6 secretion via TLR2 and TLR4. SAA-induced IL-1β does not contribute much to 
IL-6 generation.  
4.4 TLR2 and TLR4 play more critical roles in the early stage of MCP-1 
secretion in SAA-stimulated macrophages 
In this study, at a concentration of 10 µM, antagonists for TLR2 and TLR4 both 
reduced the SAA-induced MCP-1 to approximately 10% after 24 h of costimulation. 
However, this inhibition diminished after 48 h of costimulation, which only reduced 
SAA-induced MCP-1 to 50%. The diminished effects at the 48 h costimulation 





MCP-1 production. Other receptors might be involved in the later phase. Part of 
the results of this section have been published. The role of TLR2 and TLR4 in SAA-
mediated MCP-1 production has been confirmed in knockout mice in our lab120. 
Apart from monocyte recruitment, MCP-1 can facilitate oxLDL uptake by 
macrophages and promote the formation of foam cells121,122. The activation of 
TLRs in macrophages also results in oxLDL-induced foam cell formation and 
plaque instability123. SAA might be a junction between those events, i.e., SAA 
mediates MCP-1 production via TLR2 and TLR4 in macrophages, which promotes 
oxLDL uptake and foam cell formation, and finally initiates atherosclerosis. Another 
two receptors have also been investigated in our lab, and the results have 
demonstrated that FPR2 is involved in SAA-induced MCP-1 in VSMCs4, while the 
P2X7 antagonist dose not suppress MCP-1 in SAA-stimulated cells120. 
The NLRP3 inflammasome pathway was also tested in this study, and MCC950 
had no effect on SAA-induced MCP-1 production. After the activation of TLR2 and 
TLR4 by SAA, the intracellular signaling pathway including IκBα and subsequently 
NF-κB is activated and mediates MCP-1 production120. IL-1β has also stimulate 
MCP-1 gene transcription via NF-κB72. A reduction in MCP-1 has also been found 
in MCC950-treated mice124. The inability of MCC950 to inhibit MCP-1 production 
in this study might be based on low IL-1β levels and short-term stimulation. These 
results should be further evaluated in experiments with extended stimulation of 
SAA plus NLRP3 inflammasome activators. 
4.5 SAA induces nitrite production in murine macrophages via TLR2 and 
TLR4  
In addition to proinflammatory cytokines, SAA also triggers nitrite production in 
murine macrophages in this research study, which has also been shown in a 
previous study90, however no increased NO was detected in THP-1 monocytes 
and macrophages. Unlike the high level of iNOS expression in LPS-stimulated 
murine macrophages, LPS dose not upregulate iNOS expression in human 
macrophages due to the heavily methylated promoter of the human iNOS gene125. 





However, in a recent study, a relatively low level of iNOS was detected in human 
M2 macrophages83. Overall, the results of inducible NO research from murine 
experiments should be cautiously interpreted and verified. The outcome from the 
SAA-triggered NO production needs to be explored by additional experiments, 
such as in vivo studies.  
TLR2 and TLR4 are two functional receptors for SAA that trigger nitrite production 
in macrophages according to our results. Both cell membrane-expressed TLRs 
(TLR2, 4, 5) and endosomal membrane-expressed TLRs (TLR3, 7, 8, 9) have been 
demonstrated to mediate signaling transduction that upregulates iNOS104. The 
iNOS promoter contains NF-κB-binding elements that can be stimulated by TLR 
ligands126. Other activators of iNOS gene expression include IL-1β, IFN-γ and 
TNF-α106. The activation of TLR2 and TLR4 can either directly induce iNOS gene 
transcription or indirectly trigger further NO production after promoting cytokine 
secretion. The results described in a previous section have demonstrated that SAA 
mediates IL-1β production in macrophages via the NLRP3 inflammasome, but the 
blockade of this inflammasome did not reduce SAA-triggered nitrite production. 
With the significant reduction in NO production by TLR2/TLR4 antagonists, which 
was even more obvious after a 48 h costimulation, we can conclude that SAA 
triggers nitrite production in a direct way via TLR2 and TLR4 rather than through 
SAA-induced cytokines. In murine macrophages, only TLR4 but not TLR2 has 
been identified as a receptor for SAA-induced NO production50,105. The SAA-TLR2-
NO signaling pathway needs to be further confirmed.  
4.6 SAA promotes ROS generation in myeloid cells 
Due to the upregulated antioxidant systems in THP-1 cells and cultured 
macrophages, the ROS levels in LPS-stimulated THP-1 cells and RAW 264.7 cells 
are much lower than the levels in primary cells with the same stimulation127. 
However, in this study, during the early stage (2-8 h) of stimulation, the SAA-
treated cells (RAW 264.7 cells, THP-1 monocytes and THP-1 macrophages) 
generated more intracellular ROS than the control cells. Mitochondrial-derived 





study has also found intracellular ROS and mitochondrial-derived ROS in SAA-
treated mouse peritoneal macrophages69. However, intracellular ROS in this study 
were only found at the 24 h treatment, and mitochondrial ROS were detected at 
the 2 h stimulation69. These time points are far apart from those in our research. 
SAA-stimulated early ROS generation (within minutes) has also been found in 
fibroblasts80. Since ROS are a group of reactive chemical molecules, different 
fluorescent probes applied in those studies might lead to distinct results. 
ROS-induced oxidative stress also contributes to the development of 
atherosclerosis76. On the other hand, the participation of ROS in multiple cell 
signaling pathways and the consequent proinflammatory cytokine generation 
could also promote the development of this disease78. This ROS-upregulation 
property of SAA might partly explain the association found between elevated SAA 
and the increased risk of cardiovascular diseases. Since SAA-triggered ROS are 
temporary rather than continuously increased, they are thought to play a more 
critical role in cell signaling transmission.  
4.7 Reduction of SAA by CytoSorbTM adsorber 
Several case reports have verified the effect of CytoSorbTM adsorber in patients 
with severe systemic inflammatory response syndrome (SIRS)128-131. Conditions in 
those patients include post-liver transplantation, post-cardiopulmonary bypass, 
acute respiratory distress syndrome (ARDS) and postcardiac surgery128-131. 
CytoSorbTM therapy has shown benefits for SIRS patients. The reduction in 
proinflammatory cytokines (e.g., IL-6, IL-8 and MCP-1) was in parallel with the 
improvement of clinical findings during the treatment. Moreover, CytoSorbTM 
adsorber showed a good ability to reduce bilirubin, which has a neural toxicity in 
its unconjugated status128,131, while in another randomized controlled clinical trial, 
which enrolled 37 post-cardiopulmonary bypass (CPB) patients, no difference in 
the IL-6 and CRP levels was found between the control group and the CytoSorbTM 
adsorber-treated group132. Distinct patient conditions might lead to heterogeneous 
results. Compared to CPB surgery patients, patients with SIRS had a much higher 





20,000 pg/ml in ARDS-associated SIRS patients while the average peak 
concentration of IL-6 was 20 pg/ml in those post-CPB patients130.  
To our knowledge, this is the first study to investigate methods to remove SAA 
from human blood. CytoSorbTM adsorber is consists of biocompatible beads 
designed to capture and adsorb substances by size exclusion and nonselective 
hydrophobic interaction. Normally, mediators between a 5-60 kDa molecular 
weight can be adsorbed by these beads. However, after associating with HDL in 
the circulation, the molecular weight of SAA-HDL is more than 300 kDa, which 
might result in the low clearance rate of SAA in patients receiving regular dialysis 
treatment. In this study, CytoSorbTM adsorber showed a good ability to remove 
SAA from plasma, regardless of the use of recombinant or natural SAA. The SAA 
concentration in our healthy controls was approximately 6 µg/ml, and after 72 h of 
CytosorbTM adsorber treatment, this level decreased to or to below 1 µg/ml. 
Consistent with these findings, SAA level in serum interfused with 31.25 µg/ml 
recombinant SAA was reduced to below 2 µg/ml after a 72 h treatment. 
Correspondingly, this strategy reduced HDL to less than one-tenth of the original 
level. According to this parallel elimination of SAA and HDL, it is supposed that 
most of the SAA was associated with HDL in the plasma and that they were 
removed by CytoSorbTM adsorber simultaneously. However, more investigations 
are needed to understand this process and further interpret the association 
between SAA and HDL during CytosorbTM adsorber treatment.  
The original concentrations of other substances including cholesterol, triglycerides, 
phospholipids, LDL and CRP, in this study were in the normal reference range. In 
addition, they were all reduced by CytosorbTM adsorber treatment. The molecular 
weight of these substances varies from 25 kDa (CRP) to more than 300 kDa (HDL), 
and their removal cannot be explained by the size exclusion adsorb property of 
CytoSorbTM adsorber. A similar phenomenon was also found in a case report, in 
which cytokines with similar molecular weights had distinct removal rates by 
CytoSorbTM treatment131. Data for CytoSorbTM adsorber removing lipids and 





bilirubin was also greatly reduced by CytoSorbTM adsorber, which has a molecular 
weight of 584 kDa128,131. Many conditions in patients lead to changes in bilirubin 
levels, and we cannot exclude the possibility that CytosorbTM adsorber can remove 
some high molecular weight materials. 
Another issue that needs to be addressed is the much faster substances clean up 
speed in the final 24 h of CytoSorbTM adsorber treatment. During the treatment, 
samples from 5 treatment time points were collected, and bead columns were 
replaced by new ones after every 24 h. The sample volume was 10 ml at the very 
beginning, while at 48 h, only 4 ml plasma was left in the system. With the same 
CytoSorbTM adsorber volume, it is reasonable to have a faster elimination in the 
final 24 h. For the limited sample size, it is not possible to calculate the elimination 





This study demonstrates that SAA is a proinflammatory mediator in macrophages. 
Compared to a traditional PAMP (LPS), SAA showed a strong induction of IL-1β, 
IL-6, MCP-1, NO production and ROS, which provides an explanation for the 
association found between the increased SAA and the growing cardiovascular 
complications in CKD patients. 
TLR2 and TLR4 are two critical receptors for SAA-mediated cytokine and NO 
production. However, distinct patterns of those two receptors were observed in the 
production of different cytokines. For example, TLR2 and TLR4 play a more critical 
role in the early stage of SAA-induced MCP-1 production. Regardless of the 
stimulation time, SAA-generated IL-6 is more dependent on TLR4 and only partly 
on TLR2, whereas only TLR4 is responsible for SAA-induced IL-1β secretion. 
Moreover, antagonists of TLR2 and TLR4 show a substantial suppression of SAA-
triggered NO production at both 24 h and 48 h stimulation. In summary, the SAA-
triggered NO production is mainly dependent on TLR2 and TLR4, while in addition 
to these two receptors, other receptors might be simultaneously involved in SAA-
mediated cytokine generation. 
The NLRP3 inflammasome is included in this project for the intracellular signaling 
pathway investigation. This complex is only involved in the SAA-mediated IL-1β 
generation but not in SAA-induced IL-6, MCP-1 and NO production. These results 
are not consistent with previous studies, which have shown the essential role of 
IL-1β during MCP-1 and IL-6 production. The low level of IL-1β and limited 
stimulation time might be the reasons for this discrepancy. Other investigations, 
such as in vivo or in vitro experiments targeting the NLRP3 inflammasome, are 
required to further explore the role of IL-1β or the NLRP3 inflammasome in SAA-
mediated IL-6 and MCP-1 production.  
In this study, SAA could induce murine and human macrophages to generate 
intracellular ROS but could only promote murine macrophages produce 
mitochondrial ROS. ROS were found to play a critical role during NLRP3 





the low mitochondrial ROS level is responsible for the inefficiency of IL-1β release 
in THP-1 macrophages and the pathway for SAA triggering ROS need to be further 
explored. 





Considering the significant proinflammatory properties of SAA, and the sustained 
elevated SAA in dialysis patients. It is necessary to explore methods to remove 
SAA from the circulation. A mini plasma adsorption system filled with CytoSorbTM 
adsorber efficiently removed SAA from human plasma. However, CytoSorbTM 
adsorber is not specific for SAA, and can adsorb other substances, such as protein, 
CRP, triglycerides and HDL-C. An investigation designed to evaluate the capacity 
Figure 20 Signaling pathways for SAA-mediated inflammatory reactions in macrophages 
IL, interleukin; MCP-1, monocyte chemoattractant protein 1; NF-κB, nuclear factor kappa-light-
chain-enhancer of activated B cells; NLRP3, NOD-like receptor, pyrin domain containing 3; NO, 





of CytoSorbTM adsorber or SAA removal in clinical treatment has been planned. 
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